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1. Introduction
Health is widely acknowledged as an economic good representing a pre-requisite
for individual well-being and economic productivity. Public policy actions which
focus on health promotion and improvement are essential for sustainable economic
welfare, and prevention measures are often the key to successful health policies.
From a theoretical standpoint, health prevention belongs to the category of
pure public goods to which the properties of non-rivalry and non-excludability
apply. Furthermore, health promotion programs entail a long-term distribution
of the benets that make them less protable to private rms. It is, therefore,
the public sector which is mostly responsible for developing prevention programs:
sound tools for cost reductions and resource management are becoming more and
more crucial in the long-term perspective under increasing public budget con-
straints.
As early as the 1980s, prevention issues were already under study via general
schemes of cost-eectiveness, cost-benet and related analyses (see for instance
Torrance, 1986 and Birch, 1987) while a more exhaustive economic analysis is
relatively new (Haddix et al., 2003). At the same time operational approaches to
prevention strategies and application tools to support policy making were being
developed to face various organizational constraints: extensive discussion can be
found in (Teutsch, 1992). However, only a few studies still examine the impact
of prevention on public health expenditure in a comprehensive model-theoretical
framework, as in Haddix et al. (2003); Davies et al. (2003) and Mackinnon and
Dwyer (1993).
Furthermore, several studies provide evidence of the positive impact of health
promotion on relevant economic variables (labour supply, productivity, wages and
earnings: for a review see Suhrke et al., 2005). International organizations, public
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health authorities and researchers have particularly evaluated prevention measures
in public health alerts, such as wide-spread epidemics, life styles, and the erad-
ication of endemicities (Boily et al., 2007; Goldie et al., 2006; Zethraeus et al.,
2007; Kaestner et al., 2014). Following a thorough analysis of their impact, large
scale programs against obesity and measles were launched by both the O.E.C.D.
(2009) and the W.H.O. (2011), and their outcomes have formed the object of var-
ious studies (Waters et al., 2011). Similarly, Zhou et al. (2005) have extensively
evaluated the public health savings of childhood routine immunisation campaigns
in the US.
As for the various types of prevention that can be implemented on a spe-
cic population of reference, Boland and Murphy (2012) remark that \primary
prevention blocks or delays the onset of disease, avoiding direct costs associated
with diagnosis, treatment, rehabilitation and indirect costs associated with lost
function, lost work productivity and other societal costs. Secondary prevention
includes the early detection of disease e.g. through screening. Tertiary prevention
services act when a disease or injury is already present, and seek to limit the eect
of the condition and to improve quality of life, e.g. chronic disease management
programmes".By far, secondary prevention studies are more common in the liter-
ature. Studies in cancer prevention have been conducted by Holland et al. (2006);
Sasieni et al. (2009); Duy et al. (2010) and by the Medical Center Expert Group
(2011) of the Vrije Universiteit in Amsterdam, while Sassi and Hurst (2008) oer
a comprehensive analysis of the socio-economic eects of the prevention of life-
style related chronic diseases. As for primary prevention,using a decision-analytic
model, Cipriano et al. (2007) estimate the cost gains achieved by screening at birth
campaigns.
As prevention measures are implemented more widely and at the same time the
globalization of pathologies has placed higher pressure on public health budgets
worldwide, there is a growing urge to implement cost-reducing strategies where
prevention measures play a major role. However, policy makers need comparable,
easy to use and reliable planning tools to schedule interventions and evaluate
their impact. As clearly explained in Goldie (2003): \No clinical trial or single
cohort study will be able to simultaneously consider all of these components. Cost-
eectiveness analysis and disease-simulation modelling, capitalizing on data from
multiple sources, can serve as a valuable tool to extend the time horizon of clinical
trials, to evaluate more strategies than possible in a single clinical trial, and to
assess the relative costs and benets of alternative policies to reduce mortality".
This paper oers an original and overall modelling approach to designing pri-
mary and secondary prevention measures under an essentially budget-management
perspective. Based on its demographic structure and a disease epidemiology, a
reference population and a multistate distribution of pre-clinical, asymptomatic
conditions among aected individuals is here considered.
Section 2 presents a simple primary prevention model and expands it to a
multistate, secondary prevention evaluation model. Section 3 further analyses
qualitative features of the model and its mathematical relationships to variable
prevention policies. Next, in section 4 a review of the most recent statistical devel-
opments is presented with specic reference to the model parameters and in 5 an
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application to overall Italian cancer data is oered,along with further extensions
of the general model to include more complex schemes, such as disease preva-
lence instability and dierential survival experiences. Conclusions and material
for further developments are in section 6.
2. General prevention models
As remarked in the previous section, primary and secondary prevention measures
act at dierent population/disease levels and interactions. In this section preven-
tion evaluation schemes for primary and secondary interventions will be presented
with regard to expenditure and savings obtained by a public health system, with-
out a selection in the admission of the aected individuals to treatment (i.e., all
aected individuals have equal access to clinical treatment). Furthermore,the dis-
ease prevalence in absence of prevention interventions is supposed to be stable
and constant over the time horizon considered; the consequences for dropping this
hypothesis will be briey analysed in section 5, where possible extensions of the
model will be described.
A simple scheme of primary interventions may be thought of as an information
campaign directed at the general population or at a sorted proportion of it. This
roughly involves per capita expenditure and results in a reduction of the disease
incidence and prevalence, at variable levels, corresponding to the ecacy of the
campaign.
Let P = p+ p be the total number of individuals in a population, divided into
p = P individuals that will eventually become aected by some disease under
study ( being the known prevalence of the disease in the general population) and
p = (1  )P individuals that will not develop the disease.A public health system
that must treat all aected individuals has a predictable, total, disease-related
cost C given by
C = A0 +Ap (1)
where A0 is a general xed system cost and A is the variable treatment cost per
aected individual.
Thus, given a per capita prevention expenditure e and a corresponding propor-
tion  of individuals positively responding to the prevention measures, the total
cost (1) becomes
C^ = A0 +A(1  )p+ eP (2)
Note that the term P does not include already aected individuals, as they are
not the object of the prevention actions and are, therefore, included in the xed
cost term A0.
Using (1) and (2), a system saving is thus attained if
S = C   C^ = Ap  eP > 0) e < A (3)
which provides an exact evaluation of the protability of a prevention investment:
in fact, this turns out to be economically protable only when the variable treat-
ment costs and/or the disease prevalence are high enough to compensate for the
prevention costs.
406 G. Schinaia and V. Parisi
A more complex modelling scheme is to be used to evaluate secondary preven-
tion measures as these interventions aim at dierent results and involve various,
disease-related types of individuals. In this case the reference population includes
those already aected individuals at asymptomatic, pre-clinical stages, aiming at
an early detection of the disease and at its early treatment Simeonsson (1991).
Let the total population be given by P = p+p with p asymptomatic individuals
already aected by the disease under study at n increasing levels of severity, and
p healthy individuals, and let i i = 1; : : : ; n be the known prevalences of each
level of severity of the disease in the population.
Similarly to (1), the public health system in absence of prevention measures
has a predictable, total, disease-related cost C given by
C = A0 +
nX
i=1
iiP (4)
where A0 is a general xed system cost, and i, i = 1; : : : ; n are the variable treat-
ment costs per aected individual and related to the n levels of disease severity.
Note that the distribution of individuals in (4) is supposed to be induced by the
disease symptomatology: i.e., aected individuals enter the cost function (4) at a
level corresponding to detectable symptoms.
Possible prevention measures can be thought of as some form of screening
over the entire population P to detect all aected individuals before their disease
becomes symptomatic (i.e., at a lower level of severity). Let e be the unit cost of
the prevention operations; the total cost of prevention is therefore given by
eP = e
 
nX
i=1
iP + p
!
and the prevention cost per aected individual actually detected is then given by
" = e
PPn
i=1 iP
= e

1Pn
i=1 i

The eects of prevention on the number of aected individuals are thus given
by their redistribution among the n levels of severity (with the corresponding
changes in the treatment costs) according to a lower triangular transition matrixQ
= bijci;j=1;:::;n such that:
nX
i=j+1
ij  1 and ij
8<:
= 0 i < j
1 Pni=j+1 ij i = j
ij i > j
(5)
where the underlying hypotheses are:
 the disease prevalence does not change within the time horizon considered,
 prevention measures do not interact with the symptomatology of the disease
(i.e., the level of severity detected by prevention measures cannot be higher
than the level corresponding to detectable symptoms).
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By using (4), the total system cost, when prevention measures are put in place, is
thus given by
C^ = A0 +
nX
i=1
iiP +
n 1X
i=1
nX
j=i+1
ijijP  
nX
i=2
i 1X
j=1
ijiiP + "
n 1X
i=1
nX
j=i+1
jijP
(6)
where the variable treatment cost of the i-th level of severity is now given by the
algebraic sum of
 iiP : the cost of individuals detected at symptomatic level of severity;
 Pnj=i+1 ijijP : the cost of individuals detected at the i-th level of severity
with a higher symptomatic level of severity;
 Pi 1j=1 iijiP : the cost of individuals with i-th symptomatic level of sever-
ity detected at a lower level of severity;
 "Pnj=i+1 jijP : the prevention costs per individual with i-th symptomatic
level detected at a lower level of severity.
A system saving is thus attained if
S = C   C^ > 0
which, by using (4) and (6), becomes
 
n 1X
i=1
nX
j=i+1
ijij +
nX
i=1
ii
i 1X
j=1
ij   "
n 1X
i=1
nX
j=i+1
jij > 0
By using some simple algebra and solving for " we have
" <
n 1X
i=1
nX
j=i+1
(j   i)jij
n 1X
i=1
nX
j=i+1
jij
(7)
Thus an economically sound prevention policy can be eectively set up when the
cost of one asymptomatic detected individual is smaller than the average cost re-
duction, weighed by the newly detected prevalences of each level of severity. In
the absence of further, specic information on the morbidity of the disease under
study at various levels of severity (i.e., no direct or indirect information avail-
able on the ji terms), the assumptions that the whole population P undergoes
the prevention screening, and that no biased error occurs during the screening
operation, provide a reasonable ground to the conservative hypothesis that the
prevalence rates i i = 1; : : : ; n of the general population also apply to the various
levels of severity. This implies that all transitions ij can be approximated by the
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corresponding prevalence rates j 8j > i; i = 1; : : : ; n and, similarly to (3), (7)
can be expressed in terms of the unit cost e of prevention operations and becomes
e <
n 1X
k=1
k
n 1X
i=1
nX
j=i+1
ij
n 1X
i=1
nX
j=i+1
(j   i)ij (8)
Under the hypothesis of non-decreasing costs between the disease stages and the
trivial remark that i > 0 for at least two dierent i's, i = 1; : : : ; n, then e 
08ii = 1; : : : ; n and e = 0 if and only if j   i = 08j > i i; j = 1; : : : ; n.
3. Qualitative Analysis
Some further insight into the modelling approach in the previous section is pro-
vided by a thorough analysis of (8).
By dening the vectors  = [i]i=1;:::;n and  = [i]i=1;:::;n and the Hollow
matrix
B1 =
26666664
0  1  1  1     1
2 0  2  2     2
3 3 0  3     3
4 4 4 0     4
     
n n n    n 0
37777775
where In is the n n identity matrix, (8) can be re-written as
e <  2 l
0
n
tr(B21)
0B1 or e <  2 l
0
n
tr(B21)
0B2ln (9)
where ln is the n-vector with elements all equal to 1's and B2 = B1In. Vectors
,  and ln in (9) represent, respectively, the treatment cost prole of the disease
under study, the prevalence prole and the prole of an unscreened individual;
therefore, the degenerate, bilinear forms in (9) map, respectively, a prevalence
prole and an unscreened individual onto the cost space and the degenerate con-
dition accounts for the reduction of the space dimensionality as from (5).
Let us now dene the upper limit in (9) as
f () =  2 1
0
n
tr (B21)
0B21n (10)
Its derivatives with respect to each component of  provide a qualitative evaluation
of the per capita expenditure threshold for secondary prevention measures, as
explained in the previous section. While it is not reasonable to assume any direct
intervention on the disease progression, various forms of primary prevention can,
however, be implemented to actually reduce the disease incidence, which, in the
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long run, results in a decrease of 1. Using some straightforward vector calculus,
we have that df()d1 can be expressed as
df ()
d1
= g1 (;)  g2 (;) (11)
where the domain of g1 consists of the (n   1) dierences (i   1) and of all
i8i = 1; : : : ; n while the domain of g2 consists of the remaining (n 2)! dierences
(i   j) for i > j and of i 8i > 1.
When n = 3, (11) can be explicitly written out as
df()
d1
= [2(2   1) + 3(3   1)]
 (212 + 213 + 2123 + 223)  323(3   2) (12)
With reference to (12) and for selected values of 2, 3 and  the graph of f()
as a scalar function of 1 is presented in gure 1, the change of its curvature
corresponding to the solution of df()d1 = 0.
0
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250
00.020.040.060.080.10.12
f(E1)
E1
Figure 1 { Graph of f() from (10) as a scalar function of 1
It is thus evident that both g1 and g2 are non-negative and non-decreasing over
their whole domains. Under general conditions, g1  g2 and (10) increases; how-
ever, when the disease entry level prevalence 1 decreases (by some forms of pri-
mary prevention or other public health interventions) below the value where (11)
vanishes, then the allowance for secondary prevention expenses starts increasing,
due to the prevailing cost reductions of the diagnosed cases.
4. Statistical Remarks and Parameter Evaluation
Although the objective of the present paper is to illustrate the basic features
of the proposed prevention model, some statistical remarks might be of help to
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understand the global functioning of the system and the model building process.
The schemes (4) and (6) presented above are both based on a rst order ap-
proximation of an underlying compartmental system Jacquez (1996) of the health
care costs among the various levels of severity of the pathological status under
study. This amounts to limiting the model scheme to some specic time instant t0
(i.e., when no dynamic evolution is involved). A further,dynamical development
of this scheme will be the object of future research and is therefore here excluded
from these statistical remarks.
In the next, two main questions will be briey addressed, as the evaluation
of the fractional transfer coecients (FTC, see Jacquez and Simon, 1993, for a
thorough theoretical overview) involved in the compartmental transitions can be
performed using various techniques, while more statistical details can be drawn
from the specialized literature, using both standard and ad hoc methods.As shown
in Schinaia (1999), all compartmental models have a topological structure of their
FTC parameter space which, in turn, leads to a dynamical evolution of the model
output. When, as in (4) and (6), the underlying compartmental structure of the
model presents no dynamical evolution then the model output estimates C and
C^ can be regarded to as a pointwise picture of the functioning system at some t0
and dependent on the vectors  and .
In turn,  and  are to be externally determined by available longitudinal data
sets, by selecting appropriate covariates of known signicance to the pathological
status under study and by usually tting some forms of regression model. However,
more specic calculation reduction and covariate selection techniques have been
developed in the past years; articial neuronal networks (Gambhir et al., 1998),
ROC curves (Heagerty and Zheng, 2005 and Krzanowski and Hand, 2009) and
their extensions (Hand, 2009) and genetic-type algorithms (Santhoji Katare et al.,
2004) are among the most recent methods to determine accurate evaluations when
missing or incomplete data are present.
5. Applications and Extensions
As illustrations of the use of the prevention model presented in the previous sec-
tions, a numerical application to Italian global tumor data and two extensions of
the mathematical framework are here presented.
The various tumor forms are a typical example suitable to most of the mod-
elling hypotheses as in section 2; even when limited to any incidence sub-populations,
these may, however, be easily detected (male-female, for instance). In the follow-
ing simple numerical examples of prevention schemes are based on the model in
the previous section and use cancer treatment- and cost-data from heterogeneous,
external studies.
In order to implement the model extensions it must be noted that the vector
setting of the prevention expenditure limit (9) may be eectively used, by di-
rect modications of ,  and 1n, to accommodate complex prevention schemes,
such as the selection of dierential survival sub-populations and communicable
(infectious or hereditary) diseases.
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TABLE 1
Unit treatment costs and prevalence by tumor primary site
Primary Prevalence (%)* Unit cost (1000e)**
Lung 0,17 36
Stomach 0,12 19
Melanoma 0,27 21
Colon/Rectum 0,69 24
Cervix 0,05 10
Breast 2,26 17
Prostate 1,23 19
Leukemias 0,09 77
* A.I.R.TUM. { Tumors in Italy (2012) - http://www.tumori.net
** CENSIS, from Economist Intelligent Unit (2010)
5.1. An Application to Italian Cancer Data
Italian prevalence and global unit cost data corresponding to various primary
tumor sites are shown in Table 1.
While no staging data are required in this simplied application of the primary
prevention scheme as from (3), the secondary prevention scheme requires cost and
prevalence distribution data for the application of (8). For the sake of homogene-
ity of the various primary tumor sites and in order to outline the use of the model,
the staging classications have been reduced to 3 for each type of tumor on the
basis of epidemiological and clinical data drawn from the existing medical litera-
ture. However, as the detailed cost distribution at each stage is not immediately
available,a cost proportionality hypothesis was applied to the data in Table 1 and
the resulting expenditure limits were computed according to (8).
Figures 2 and 3 show two examples of primary prevention schemes where: the
expenditure limits are mapped against the corresponding total prevalences, and
the expenditure limits are mapped against the total unit treatment costs.
A visual inspection of gures 2 and 3, shows that the secondary prevention
expenditure limit is approximately linearly correlated to the pathology prevalence,
while no direct dependency can be detected between the expenditure limit and the
unit treatment cost.
5.2. Variable Stage Survival
Let us suppose that an aected individual has a life expectancy at disease onset
time t given by E(t) =
1R
t
S(w)
S(t) dw. Since, in general, the exact time of disease
onset is unknown, the disease staging may be eectively used to approximate the
survival experience as a discrete function of the severity level rather than the time
elapsed: Si, i = 1 : : : n. Thus, the corresponding life expectancies Ei =
nP
h=i+1
Sh
Si
generate a new set of costs, where original average stage costs i, i = 1 : : : n are
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Figure 2 { Tumor types by primary prevention expenditure limit and prevalence.
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Figure 3 { Tumor types by primary prevention expenditure limit and unit treatment
cost.
Modelling prevention strategies in public health 413
associated with life expectancy at each detection stage: iEj , i 6= j; j = 1; : : : ; n
and (9) turns into
es <  2 l
0
n
trB21
0B2E
where E = [Ei]i=1;:::;n.
5.3. Communicable diseases
The extension of the model to communicable diseases prevention must account for
all secondary cases that an unscreened individual may potentially generate, during
his whole infectious life. Not very dierent are cases of hereditary syndromes and
all sorts of aections.
Similarly to the previous section, vector ln turns into ln + s = [1 + si]i=1;:::;n,
where the si, i = 1; : : : ; n are the average numbers of secondary cases generated
by an infectious individual in stage i, i = 1 : : : n Therefore, (9) becomes
es <  2 l
0
n
tr(B21)
0B2(ln + s)
and, similarly to the previous case, new stage costs are generated as i(1 + sj),
i 6= j; j = 1; : : : ; n.
6. Conclusions
This paper has presented a model to evaluate the eects of primary and secondary
prevention schemes with regard to expenditure and cost savings for a public health
system. Focussing on cost issues, the model does not take into consideration social
(or equity) issues that we assume have no part in the approach here presented.
Model assumptions are common to most countries where health care is primar-
ily public (i.e., the whole population has equal access to health care), the disease
is locally endemic and prevention measures do not interact with the symptoma-
tology of the disease. As expected, the analysis shows that a primary prevention
scheme is protable when costs and/or the disease prevalence are high enough to
compensate for the prevention costs and the model provides an appropriate nu-
merical evaluation. Moreover, given dierent levels of disease severity, a secondary
prevention measure is economically sound when its eld costs are smaller than its
overall potential treatment costs.
Qualitative features of the model are further analysed under functional hy-
pothesis to relate primary and secondary interventions. A numerical example of
Italian tumor data shows a direct application of the model.
As shown in section 4, the prevention model proves to be exible enough to
incorporate more complex assumptions, namely dierential survival groups and
communicable (infectious or hereditary) diseases.
As a last remark, this scheme can be extended to broader and longer term
planning when larger data sets are observed and made available. In such a case,
corresponding to adequate statistical and nancial evaluations, the model can
incorporate cost actualization and longitudinal dynamics.
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Summary
Various schemes of prevention measures in public health are developed and
analyzed on the basis of a general mathematical model. Features related to cost
issues, including primary and secondary prevention interventions, dierential sur-
vival experiences and communicable diseases are in turn used to show the poten-
tialities of the theoretical framework. Statistical estimation procedures are briey
discussed and a numerical application is presented with reference to Italian cancer
data.
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